| 0.5339 0 (0%) | 01-18 15:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Ayala Pharmaceuticals, Inc. (AYLA) operates as a clinical-stage oncology firm, concentrating its efforts on discovering, developing, and ultimately commercializing small molecule treatments designed for individuals afflicted by rare and aggressive cancers. A key asset in its pipeline is AL101, an injectable, potent, and highly selective small molecule gamma secretase inhibitor (GSI). This candidate is currently in Phase II clinical trials, specifically targeting recurrent or metastatic adenoid cystic carcinoma in patients whose disease is characterized by Notch-activating mutations. Additionally, the company is advancing AL102, an oral, potent, and selective small molecule GSI, which is undergoing a pivotal Phase II/III study for the management of desmoid tumors. Ayala Pharmaceuticals has also entered into a collaboration agreement with Novartis International Pharmaceutical Limited to explore the development of AL102 for addressing multiple myeloma. The company, founded in 2017, maintains its headquarters in Rehovot, Israel.
Thu, 19 Jan 2023
Cancer treatment developers Ayala Pharmaceuticals and Advaxis complete merger - The Business Journals
Wed, 19 Oct 2022
Cancer treatment developers Ayala Pharmaceuticals and Advaxis to merge - The Business Journals
Sun, 10 May 2020
Ayala Pharmaceuticals raises $55m in Nasdaq IPO - Globes - Israel Business News
Fri, 10 Jul 2015
Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis $ADXS - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|